Open in interactive viewer → charts, metric popovers & call review

Myomo Hit Breakeven — Then Quietly Shrank Its Own Funnel

Record revenue, 71% gross margin and a zero-adjusted-EBITDA print, part-paid in shares — while pipeline adds fell to 600 and management retired the 1,000-lead target it once promised
MYO · Earnings Call · 2026-11-09

The Quarter That Looked Like an Inflection

On the surface, Myomo's third quarter is the one the model finally delivered. Revenue hit a record $12.3M, up 22%; gross margin went to 71.3% from 63.8%; operating expenses grew just 6%; and adjusted EBITDA landed at roughly breakeven versus a $2.7M loss a year ago. The engine behind it is the MyoConnect program, now in its second year: patients from rehab hospitals, stroke clinics, O&P partners and the VA were 54% of revenue versus 33% a year prior — the recurring patient sources transition management has been promising for four quarters. Twelve million dollars a quarter is a record, but it is also barely different from the prior three quarters — the growth is real, the level is not yet transformative. Gross margin of 72% in the last reported quarter is genuinely medical-device-grade, and the low-70s guide for 2027 implies it holds. Then there is the fine print, which the CFO volunteered rather than hid:

Note that a portion of the improvement in adjusted EBITDA is due to higher stock based compensation expense, as certain employee incentive payments were paid in stock during the third quarter as part of our cash management initiatives.

David A. Henry, Chief Financial Officer · 2026-11-09
That is a subtle but important admission. Adjusted EBITDA is struck before stock based compensation expense, so paying employees in equity instead of cash flatters the very metric being celebrated. Roughly a dollar of every twelve of revenue was paid in shares last quarter, up 164% year over year. Meanwhile GAAP net loss widened to $4.2M from $3.7M, thanks to a $1.8M non-cash mark on the derivative liability tied to the Avenue Capital cash burn financing. And the balance sheet is thinner than the $11.9M headline: effective net cash after debt was under $1M in the last reported quarter, down 93% year over year.

The Funnel Shrank, and the Metric Got Redefined

Here is the real story of the quarter. Pipeline adds came in at 600, down sequentially, with MyoConnect referrals only 18% of them. The CFO blamed summer scheduling at referring sites, "temporary internal staffing constraints" and "an inefficiency in our lead generation" on the direct-to-consumer side. Analyst Chase Knickerbocker put it plainly: “We have not seen the seasonality in Q3 before.” — Chase Knickerbocker, Analyst · 2026-11-09 That matters because the top of the funnel was, for two years, the number this company staked its credibility on. In May 2025, with 700 adds reported, the exchange went like this: “I think that you're thinking the way that we're thinking, Scott. If we're going to get to the kinds of revenues that we're looking to achieve, we obviously have to cross over 1,000 at some point.” — Dave Henry, Chief Financial Officer · 2025-05-07 Sixteen months later, the framing has inverted: “That is the other way to say it, you know, 800 pipeline ads yesterday is not the same as 800 pipeline adds in the future because of this transition we are making toward recurring patient sources.” — David A. Henry, Chief Financial Officer · 2026-11-09 The pipeline ad count is no longer the thesis; the hit rate is. To be fair, the quality argument is substantiated rather than invented. Referred patients arrive pre-screened by clinicians who know both the clinical inclusion criteria and the local payer map, and the CFO claims “about 10x MyoConnect pipeline adds turn into revenue at a rate 10x better than direct to patient advertising” — David A. Henry, Chief Financial Officer · 2026-11-09. ASP rose 2% to ~$55.5K; record 258 orders converted into a record 222 revenue units; and the same-store effect is real, with “same store sales growth of over 30%” — Paul R. Gudonis, Chief Executive Officer · 2026-11-09 from referring sites already experienced with the device. But the honest reading is that one channel broke while the other has not yet scaled. Of 500-plus MyoConnect locations, more than 200 were added in the last quarter alone — and Paul Gudonis conceded most are still referring their first patient: “typically just on their first patients” — Paul R. Gudonis, Chief Executive Officer · 2026-11-09. The 12-week therapy protocol plus insurance lag means the second and third referrals are a 2027 event, not a 2026 one. Guidance was narrowed to the top of the prior range, $46–47M, not raised.

What Management Stopped Talking About

The most telling absence is the advertising platform. Through mid-2025, Meta's healthcare privacy changes were a headline topic — Paul Gudonis explaining lookalike audiences and a pivot to targeted TV. On this call, an analyst offered up Google AI Overviews as the culprit and the CFO replied, “most of it comes from meta. So, I am not sure if Google and whatever issues that they had... had much of an impact with respect to our pipeline adds in third quarter.” — David A. Henry, Chief Financial Officer · 2026-11-09 The lead generation problem is now generic operating friction rather than a named, solvable platform issue. Also quietly subsumed: the O&P channel, which dominated the 2024–2025 keyword sets as the great white-space distribution bet, is now 8% of revenue and referenced mainly as a conference. It did not fail — it melted into MyoConnect. And 3D printing of custom shells, a cost lever first flagged in Q3 2025, finally gets its own line as an in-sourcing program coming online by year-end.

What Actually Got Stronger

Payer access did. Agreements covering an additional 35 million lives, seven state Medicaid enrollments with more queued, and a mechanism the market may be underrating: “where we get enrolled in-network with state Medicaid plans, those plans will often pay for the secondary co-pay for Medicare part B patients. So that helps, raise our ASP” — Paul R. Gudonis, Chief Executive Officer · 2026-11-09. Being a network provider converts an appeals process into an authorization — the single highest-leverage fix available to this business, and one that plays directly against the industry's Medicare Advantage membership cost-containment machine. Yet the market has already voted. Price-to-revenue sits near 1.0x on a $48M market cap — a valuation that implies either a capital raise or a stall. The stock peaked at $1.86 on August 19 and was 32% below that level entering this print, so a beat-and-narrow quarter landed into a tape that had stopped paying for the story. When a company trades at one times sales with 71% gross margins, the debate is never about the quarter. It is about whether the funnel is a small, high-converting, referral-led annuity — or a machine that got harder to feed.